newsfilter
← Latest News
GlobeNewswire·

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has